22:31 , Mar 16, 2017 |  BC Extra  |  Financial News

Aerpio raises $40M ahead of planned OTC listing

Aerpio Pharmaceuticals Inc. (Cincinnati, Ohio) raised $40 million in a private placement and completed a reverse merger. President and CEO Joseph Gardner told BioCentury the transactions are part of a stepwise process in which the...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

AKB-4924: Phase Ia started

Aerpio began a double-blind, placebo-controlled, Canadian Phase Ia trial to evaluate single doses of 20, 60, 120, 240, 360 and 480 mg oral AKB-4924 in up to 48 healthy male volunteers. Aerpio Therapeutics Inc. ,...
08:00 , Feb 15, 2016 |  BC Week In Review  |  Clinical News

AKB-9778: Additional Phase IIa data

Additional data from the double-blind, U.S. Phase IIa TIME-2 trial in 144 patients with DME showed that twice-daily 15 mg subcutaneous AKB-9778 with and without once-monthly Lucentis ranibizumab led to a >=2-step improvement on the...
01:19 , Oct 7, 2015 |  BC Extra  |  Company News

Management tracks

Neurology company Rodin Therapeutics Inc. (Cambridge, Mass.) named Adam Rosenberg CEO. Rosenberg was CEO of Teleos Therapeutics (Medford, Mass.). Oncology play Tracon Pharmaceuticals Inc. (NASDAQ:TCON) named Ronald Shazer CMO. Shazer was senior director and clinical...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

AKB-9778: Phase IIa data

Top-line data from the double-blind, U.S. Phase IIa TIME-2 trial in 144 patients showed that twice-daily 15 mg subcutaneous AKB-9778 plus once-monthly Lucentis ranibizumab significantly reduced CST from baseline to 3 months, the primary endpoint,...
01:19 , Jul 16, 2015 |  BC Extra  |  Clinical News

Aerpio combo tops Lucentis alone in DME study

Aerpio Therapeutics Inc. (Cincinnati, Ohio) said a combination of its AKB-9778 and Lucentis ranibizumab was superior to Lucentis alone in the Phase IIa TIME-2 study to treat diabetic macular edema (DME). The combination met the...
07:00 , May 14, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Hypoxia-inducible factor 1α (HIF1A; HIF1-α)

Infectious disease INDICATION: Urinary tract infection (UTI) Cell culture and mouse studies suggest stabilizing HIF1A could help prevent or treat UTIs caused by uropathogenic Escherichia coli (UPEC). In UPEC-infected human uroepithelial cells, the HIF1A stabilizer...
07:00 , Mar 16, 2015 |  BC Week In Review  |  Clinical News

AKB-9778: Additional Phase Ib/IIa data

Additional data from the open-label, dose-escalation, U.S. Phase Ib/IIa TIME-1 trial in 18 evaluable patients with DME showed that twice-daily subcutaneous AKB-9778 at doses of >=15 mg for 28 days improved BCVA by >=5 letters...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Clinical News

AKB-9778: Completed Phase II enrollment

Aerpio completed enrollment of 144 patients in the double-blind, placebo-controlled, U.S. Phase II TIME-2 trial comparing 15 mg subcutaneous AKB-9778 twice daily with and without monthly Lucentis ranibizumab for 3 months vs. Lucentis alone. Aerpio...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Financial News

Aerpio Therapeutics completes venture financing

Aerpio Therapeutics Inc. , Cincinnati, Ohio   Business: Ophthalmic, Autoimmune, Dermatology   Date completed: 4/23/14   Type: Venture financing   Raised: $18 million   Investors: OrbiMed Advisors; Novartis Venture Funds; Satter Investment Management; Kearny Venture...